Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
167.8 USD
-1.03%
Market Closed
Updated:
Apr 25, 2024
Abbvie Inc
Operating Expenses
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Operating Expenses Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$19.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$11.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$11.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-20%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Operating Expenses
-$2.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-23%
|
See Also
What is Abbvie Inc's Operating Expenses?
Operating Expenses
-19.5B
USD
-19.5B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Operating Expenses amounts to -19.5B USD.
What is Abbvie Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-9%
-9%
Over the last year, the Operating Expenses growth was 9%. The average annual Operating Expenses growth rates for Abbvie Inc have been -4% over the past three years , -8% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
